How wild-type TP53 is inactivated in undifferentiated-type gastric carcinomas:: Analyses of intratumoral heterogeneity in deletion and mutation of TP53

被引:14
|
作者
Yoshimura, Akinobu
Sugihara, Hiroyuki [1 ]
Ling, Zhi-Qiang
Peng, Dun-Fa
Mukaisho, Ken-ichi
Fujiyama, Yoshihide
Hattori, Takanori
机构
[1] Shiga Univ Med Sci, Dept Pathol, Otsu, Shiga 5202192, Japan
[2] Shiga Univ Med Sci, Dept Internal Med, Otsu, Shiga 5202192, Japan
关键词
deletion; gastric carcinoma; genetic lineage; intraturnoral heterogeneity; loss of heterozygosity; mutations; TP53;
D O I
10.1159/000093090
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective: In undifferentiated-type gastric carcinoma (UGC), inactivation of TP53 is infrequent at early stages and comparable to tubular adenocarcinomas (TUBs) at advanced stages. To clarify how TP53 inactivation relates to histogenesis of UGCs, we examined p53 alterations in multiple samples of individual UGCs. Methods: We used 27 UGCs including 12 mixed types with minor tubular component (TC) and 16 with a layered structure (LS), a histological remnant of incipient signet ring cell carcinoma (SIG). We examined p53 expression immunohistochemically and analyzed loss of heterozygosity (LOH) with four microsatellite markers within 17p13.1 in multiple microdissected samples. DNA sequence of mutation hot spots in TP53 was determined in representative samples of each tumor. Results: In the mixed-type UGCs, 5 and 1 of the 8 tumors without LS showed global and regional loss of wild-type TP53, respectively, through mutation and LOH, and one fourth of the tumors with LS showed the regional loss. In the tumors with the mutation, the mutation pattern was identical between TC and poorly differentiated major component. Conclusion: The inactivation of wild-type TP53 is an earlier event before dedifferentiation of TUB to mixed-type UGC, but is less frequent and a later event in a subset of mixed-type UGC deriving from SIG. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:40 / 49
页数:10
相关论文
共 50 条
  • [1] Expression of wild-type and mutated TP53 in breast carcinomas
    Baumbusch, LO
    Myhre, S
    Langerod, A
    Bergamaschi, A
    Johnsen, H
    Geisler, S
    Lonning, PE
    Borresen-Dale, AL
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S53 - S53
  • [2] Wild-type sequence of TP53, intron 7
    Eicheler, W
    Baumann, M
    RADIATION RESEARCH, 2001, 155 (04) : 641 - 641
  • [3] Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
    Gurzu, Simona
    Jung, Ioan
    Sugimura, Haruhiko
    Stefan-van Staden, Raluca Ioana
    Yamada, Hidetaka
    Natsume, Hiroko
    Iwashita, Yuji
    Szodorai, Rita
    Szederjesi, Janos
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 12 (07) : 741 - 755
  • [4] Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
    Simona Gurzu
    Ioan Jung
    Haruhiko Sugimura
    Raluca Ioana Stefan-van Staden
    Hidetaka Yamada
    Hiroko Natsume
    Yuji Iwashita
    Rita Szodorai
    Janos Szederjesi
    World Journal of Gastrointestinal Oncology, 2020, (07) : 741 - 755
  • [5] Poor survival with wild-type TP53 ovarian cancer?
    Wong, Kwong-Kwok
    Izaguirre, Daisy I.
    Kwan, Suet-Yan
    King, Erin R.
    Deavers, Michael T.
    Sood, Anil K.
    Mok, Samuel C.
    Gershenson, David M.
    GYNECOLOGIC ONCOLOGY, 2013, 130 (03) : 565 - 569
  • [6] CRISPR screens are feasible in TP53 wild-type cells
    Brown, Kevin R.
    Mair, Barbara
    Soste, Martin
    Moffat, Jason
    MOLECULAR SYSTEMS BIOLOGY, 2019, 15 (08)
  • [7] NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells
    Zhang, Yu
    Yu, Hao
    He, Mengyao
    Liu, Wenchao
    Xiao, Shengyou
    Wang, Xiangting
    Huang, Ping
    Huang, Qiang
    NEOPLASMA, 2024, 71 (03) : 255 - 265
  • [8] Reply to "CRISPR screens are feasible in TP53 wild-type cells"
    Haapaniemi, Emma
    Botla, Sandeep
    Persson, Jenna
    Schmierer, Bernhard
    Taipale, Jussi
    MOLECULAR SYSTEMS BIOLOGY, 2019, 15 (08)
  • [9] Dissecting the functional impairment of wild-type Tp53 in human glioblastoma
    Garcia-Montano, Leopoldo A.
    Munoz, Yamhilette Licon
    Martinez, Frank
    Gallegos, Kandee
    Kang, Huining
    Piccirillo, Sara G.
    CANCER RESEARCH, 2023, 83 (07)
  • [10] Immunoprofile of tumour cells, in wild-type- versus mutant TP53 gastric carcinomas
    Gurzu, S.
    Sugimura, H.
    Van Staden, R. I.
    Jung, I.
    VIRCHOWS ARCHIV, 2020, 477 : S185 - S185